Ipamorelin vs Sermorelin
Research Verdict
Neither compound has a universal evidence advantage. Research distinction: ipamorelin goals vs. sermorelin goals.
Quick Answers
Which is better, Ipamorelin or Sermorelin?
Neither compound has a universal evidence advantage. Research distinction: ipamorelin goals vs. sermorelin goals.
What is the key difference between Ipamorelin and Sermorelin?
Sermorelin is GHRH(1-29) - acts on pituitary GHRH receptors; ipamorelin is a GHRP - acts on ghrelin/GHS receptors. They stimulate GH through completely different receptor mechanisms, which is why the combination is frequently used.
Evidence Comparison
Sermorelin: FDA-approved (withdrawn commercially 2008, now compounded), adult GH deficiency RCT data. Ipamorelin: Phase 2 post-operative ileus data only; no FDA review as a therapeutic. Sermorelin has the regulatory pedigree; ipamorelin has the better selectivity profile.
Evidence Context Favoring Ipamorelin
Research requiring a GH secretagogue with GHRP mechanism and no cortisol/LH effects - ipamorelin's selectivity is its defining advantage.
Evidence Context Favoring Sermorelin
Research requiring FDA-reviewed human GH stimulation data; sermorelin's regulatory history provides a reference standard.
Side-by-Side Snapshot
| Evidence grade | Ipamorelin: Level B Sermorelin: Level B |
|---|---|
| Research status | Ipamorelin: Phase 2 Sermorelin: Historical FDA Approval |
| Primary category | Ipamorelin: Growth Hormone Sermorelin: Growth Hormone |
| Cited studies | Ipamorelin: 3 Sermorelin: 2 |